Qiagen is reported to be evaluating strategic options, including possible sale discussions with multiple potential buyers, according to market reports. The life‑science tools and diagnostics firm’s board is working with advisers as interest from U.S. strategics surfaced, reviving takeover speculation that previously surfaced during Thermo Fisher’s aborted 2020 approach. Qiagen did not publicly comment; investors and sector analysts note the company’s diagnostic portfolio and molecular workflows make it an acquisition candidate amid renewed demand for diagnostic and genomic infrastructure assets.